AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 73 min read$ANIP

ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 revenue of $266 million, up 25.9% year on year, topping estimates by 2.4%. Non-GAAP EPS was $2.21, 8.2% above consensus. Full-year revenue guidance was $1.11 billion at the midpoint, about 1% below estimates. Shares fell 7.4% to $76.53 after results.

Original reporting
financialcontent.com
Published Aug 7, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance — source image
Source · financialcontent.com
Decision brief

The 30-second read

$ANIPNeutralMed
01

Why it matters

Traders likely focused on the full-year revenue guidance midpoint being 1% below analysts’ estimates, despite the quarter’s top-line and EPS outperformance.

02

Market read

This is a guidance-sensitive earnings reaction: the quarter looked strong, but the forward revenue outlook was marginally weaker than expected.

03

What to watch

Margin contraction in Q2 (adjusted operating margin down year over year) could be temporary from expense growth tied to the rare-disease sales force expansion.

Relevance 8/10Novelty 7/10Timing: post-Q2 report, same-day reaction

Background

ANI Pharmaceuticals delivered Q2 CY2026 results with revenue and EPS beats, alongside a rare-disease sales force expansion.

Company-level read

Ticker impact

$ANIPNeutralMedium confidence
Context

ANI Pharmaceuticals reported Q2 CY2026 revenue of $266M, beating estimates, but its full-year revenue guidance midpoint of $1.11B missed by 1%.

Expected impact

Near-term downside bias versus guidance-sensitive traders; upside limited unless management raises FY revenue outlook.

Evidence & confidence

The article cites a concrete guidance miss and a same-day stock drop of 7.4% to $76.53, indicating the market prioritized forward revenue over the quarter’s beat.

Market effects

Sector

Rare-disease and specialty pharma investors may reprice guidance risk even when quarterly revenue beats.

Regional

Primarily US small/mid-cap healthcare sentiment via ANIP’s guidance reaction.

Global

Limited, company-specific read-through to specialty pharma guidance expectations.

Counterpoint

What could challenge this read

The guidance miss is only 1% below estimates, while Q2 sales growth was strong at 25.9% YoY, suggesting the selloff may be overdone.

Key entities

  • company
    ANI Pharmaceuticals

    Reported Q2 CY2026 revenue and EPS beats, but guided full-year revenue slightly below consensus; shares fell 7.4% after the report.

Read at source← All news

Related articles

AUG 7
$ANIPMed

ANI Pharmaceuticals revenue rises 25.9% to $266M

ANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.

grafa.com3 min
AUG 7
$ANIPMed

ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue

ANI Pharmaceuticals’ Q2 2026 earnings call covered Cortrophin Gel gout expansion and guidance. CEO Nikhil Alwani said sales force reps expanded to 180 by end-June, with over 95% generating multiple patient cases. Full-year Cortrophin guidance was trimmed to $520-$540 million, citing first-half performance and factors beyond case counts. Operating leverage investment is expected to drive improved margins in 2027.

finance.yahoo.com4 min
AUG 7
$ANIPMed

ANI PHARMACEUTICALS INC (ANIP): Results of Operations and Financial Condition

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 anip-20260807xexx991.htm EX-99.1 Document Exhibit 99.1 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results • Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year • Purified Cortrophin ® Gel net revenues of $117.1 million, an

SEC EDGAR 8-K6 min
AUG 7
$ANIPMedAI 8/10

ANI Pharmaceuticals Reports Second-Quarter 2026 Results, Raises Cortrophin Gel Guidance and Reaffirms Full-Year Outlook

ANI Pharmaceuticals (Nasdaq: ANIP) reported Q2 2026 net revenues of $266.0 million, up 25.9% year over year. Cortrophin Gel net revenues rose to $117.1 million (+43.5%). GAAP net income available to common shareholders was $24.7 million, and adjusted non-GAAP diluted EPS was $2.21. The company raised Cortrophin Gel guidance to $520-$540 million and reaffirmed full-year 2026 net revenue $1,080-$1,140 million and adjusted EBITDA $285-$300 million.

quiverquant.com6 min